Literature DB >> 3396614

Metabolism of detomidine in the rat. I. Comparison of 3H-labelled metabolites formed in vitro and in vivo.

J S Salonen1, E M Suolinna.   

Abstract

The biotransformation of detomidine, a new alpha 2-adrenoceptor agonist, was studied using rat as the model animal. In vivo metabolism of the tritiated drug was compared to in vitro incubations with liver homogenates and intact, isolated hepatocytes. Metabolites were analysed by HPLC with radioactivity detection. The metabolic patterns in all systems were closely related. HPLC of urine gave twelve radioactive peaks. Tritiated water and unchanged 3H-detomidine were minor components. The two major peaks were tentatively identified as hydroxylated detomidine (14%) and its O-glucuronide (43%). Sulphate conjugates were not found. Isolated hepatocytes converted detomidine to the same two major products; the relative amount of the glucuronide increased with incubation time. In liver post-mitochondrial supernatant, hydroxylation was the dominant reaction, and the hydroxylated product comprised 74% of the total metabolites with non-induced and 50% with phenobarbital-induced liver. The major biotransformation in rat was thus concluded to be hydroxylation by the liver monooxygenases followed by glucuronic acid conjugation. The maximal rate of oxidation or the enzymatic capacity of a whole liver was estimated to be at least 100 nmol/min allowing for a high hepatic extraction ratio for detomidine. Together with the effective excretion of the glucuronide, this reaction sequence alone could account for the rapid elimination of the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396614     DOI: 10.1007/BF03189929

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

Review 1.  Preparation of isolated rat liver cells.

Authors:  P O Seglen
Journal:  Methods Cell Biol       Date:  1976       Impact factor: 1.441

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Pharmacokinetics of detomidine.

Authors:  J S Salonen
Journal:  Acta Vet Scand Suppl       Date:  1986

4.  Study by mass spectrometry of amino acid sequences in peptides containing histidine.

Authors:  J F Vliegenthart; L Dorland
Journal:  Biochem J       Date:  1970-04       Impact factor: 3.857

5.  Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450.

Authors:  S Rendić; F Kajfez; H H Ruf
Journal:  Drug Metab Dispos       Date:  1983 Mar-Apr       Impact factor: 3.922

6.  Pharmacological evidence for the involvement of alpha-2 adrenoceptors in the sedative effect of detomidine, a novel sedative-analgesic.

Authors:  R Virtanen; H Ruskoaho; L Nyman
Journal:  J Vet Pharmacol Ther       Date:  1985-03       Impact factor: 1.786

7.  Cardiovascular and sedative alpha-adrenoceptor effects of detomidine-like arylalkyl imidazoles and associated derivatives.

Authors:  J M Savola; H Ruskoaho; J S Salonen; J Puurunen; A Karjalainen; K Kurkela; N T Kärki
Journal:  Arzneimittelforschung       Date:  1988-01

8.  Bedside micro-method for measuring effective hepatic blood flow, with use of first-order galactose clearance pharmacokinetics.

Authors:  E B Rypins; H Sankary; M J Wynn
Journal:  Clin Chem       Date:  1985-09       Impact factor: 8.327

  8 in total
  2 in total

1.  Identification of detomidine carboxylic acid as the major urinary metabolite of detomidine in the horse.

Authors:  J S Salonen; L Vuorilehto; M Gilbert; G A Maylin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

2.  Metabolism of detomidine in the rat. II. Characterisation of metabolites in urine.

Authors:  J S Salonen; L Vuorilehto; M Eloranta; A Karjalainen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Jan-Mar       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.